header logo image


Page 800«..1020..799800801802..810820..»

Glaucoma Surgery Devices Market is Expected to Register Lucrative Growth 2026 – Downey Magazine

November 22nd, 2019 5:54 pm

Glaucoma is an ocular disease which affects the optic nerve of the iris and progression of the same results in vision loss and blindness. According to the World Health Organization (WHO), glaucoma is the most cause of blindness across the world.

Currently, there are no existing treatments for glaucoma; however, some commercially available therapies focus on reducing the intraocular pressure, which is responsible for the development and progression of the disease. The treatment for glaucoma starts with topical eye drops, which is an alternative used to delay surgery.

Photodynamic therapy and laser therapy are effective solutions that perform well with surgery options. Rise in the number of glaucoma cases, easy availability of medical insurance coverage for diagnosis and treatment, and growth in demand for minimally invasive glaucoma surgeries are expected to drive the global glaucoma surgery devices market during the forecast period. Furthermore, increase in health care expenditure and rise in geriatric population are expected to fuel the glaucoma surgery devices market during the forecasted period.

Request a Brochure of Glaucoma Surgery Devices Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40916

The global glaucoma surgery devices market can be segmented into types of product, types of surgery, end-user, and region. Based on product type, the market is segregated into punches, USC planer, USC marker, USC shaver, Alger brushes and probes, forceps, glaucoma drainage devices, knives, and others. In terms of types of surgery, the glaucoma surgery devices market can be divided into minimally invasive glaucoma surgeries (MIGS), tube shunt implantation, trabeculectomy, cyclophotocoagulation, and others.

Among these segments, the MIGS segment is anticipated to dominate the market during the forecasted period owing to rising demand for minimally invasive and patient-friendly procedures. Based on end-user, the glaucoma surgery devices market can be categorized into diagnostic centers, eye-hospitals, and others.

The global glaucoma surgery devices market has a presence of several regional players which have a huge market share in emerging countries operating at regional or country level. In terms of geography, the global glaucoma surgery devices market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The U.S. dominates the market due to the increase in acceptance of treatment options.

Additionally, rising awareness among patients regarding glaucoma and the introduction of favorable reimbursement policies are anticipated to fuel the glaucoma surgery devices market in North America during the forecast period. Europe is the second largest market for the glaucoma surgery devices market.

Request for a Discount on Glaucoma Surgery Devices Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=40916

The market in Asia Pacific, especially in countries such as India, China, and Japan, is anticipated to expand at a rapid pace in the next few years due to rising awareness regarding glaucoma surgeries and booming medical tourism in this region. The market in Middle East and Africa and Latin America is projected to expand at a sluggish pace in the near future.

Major players operating in the global glaucoma surgery devices market are Abbott Laboratories, Glaukos Corporation, Alcon, Inc., ASICO, Carl Zeiss Meditec AG, Katalyst Surgical, Nidek Co., Ltd., Lumenis Ltd., Ziemer Ophthalmic Systems AG, and Iridex Corporation.

Continue reading here:
Glaucoma Surgery Devices Market is Expected to Register Lucrative Growth 2026 - Downey Magazine

Read More...

Ophthalmic Knives Market is Expected To Increase Up to US$ 460 mn by 2027 – Downey Magazine

November 22nd, 2019 5:54 pm

Ophthalmic knives, also known as microsurgical knives, are specifically designed for uncomplicated and hassle-free eye surgeries. Ophthalmic knives are available in different shapes and angles for accurate incisions in the cornea and sclera during an eye surgery. These knives consist of blades that are strong and break-resistant, and made of different materials such as stainless steel, diamond, sapphire, and silicon to provide sharpness and an accurate opening.

Growth of the globalophthalmic knives marketis attributed to increase in the global geriatric population, which is more prone to cataracts and refractive eye errors. Moreover, increase in the incidences of glaucoma, vitreoretinal, diabetes retinopathy, corneal transplantation, and technological advancements are boosting the growth of the global ophthalmic knives market.

North America dominated the global ophthalmic knives market in 2018, and this trend is anticipated to continue during the forecast period. This is attributed to rise in the prevalence of ophthalmic diseases, awareness about minimal invasive surgeries, and surge in vision impairment in the region.

However, increase in the number of local manufacturers is creating a pricing pressure, which is likely to hamper the growth of the global ophthalmic knives market in North America in the latter half of the forecast period. Asia Pacific is expected to be a highly lucrative market for ophthalmic knives during the forecast period.

Request a Sample of Ophthalmic Knives Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=66695

High Prevalence of Eye Disorders and Rise in Awareness to Drive Usage of Ophthalmic Knives

The incidences of eye diseases has increased across the globe, and is expected to rise significantly in the near future. Ophthalmic disorders that need surgery are cataract, glaucoma, age-related muscular disorders, corneal transplantation, and others. Globally, eye disorders such as cataract, glaucoma, andage-related macular degeneration(AMD) are the leading causes of blindness and visual impairment. The high prevalence of eye disorders is fueling the demand for minimal invasive surgeries with ophthalmic knives.

Cataract is the most prevalent eye disorder across the globe. Hence, the demand for eye surgeries to treat this disorder is high. Rise in cataract surgeries has induced manufacturers to focus on developing efficient and versatile ophthalmic knives. According to the NCBI journal, the rate of blindness caused by cataract is rising at 1 million per year, globally, and the number of people undergoing cataract operations is increasing by 4 million to 5 million per year.

According to a WHO report (2010), glaucoma was estimated to cause blindness in 4.5 million people, which is around 12% of all global blindness, while AMD was the third-leading cause of blindness after cataract and glaucoma, with a global prevalence of 8.7%.

The incidences of eye disorders such as cataract are expected to rise, due to the increase in the geriatric population. According to research, the prevalence of cataract is three times higher in India compared to that in the U.S., with 82% people in India aged between 75 years and 83 years affected by cataract as compared to only 46% in the U.S. in the same age group.

Increase in Geriatric Population Increases the Need of Surgeries

The geriatric population is likely to suffer from cataract more often than the younger population. Moreover, the geriatric population is increasing at a faster pace than the younger population.

Increase in the geriatric population aged above 65 years is projected to surge the incidences of eye disorders, which, in turn, is anticipated to boost the need for corrective surgeries and treatment of these disorders. Eye surgeries require ophthalmic knives for successful incisions. These factors are likely to boost the global ophthalmic knives market.

According to the United Nations, the geriatric population aged above 60 is expected to double by 2050 and triple by 2100, an increase from 962 million in 2017 to 2.1 billion in 2050, and 3.1 billion by 2100.

Adoption of Technologically-Advanced Blades

Technological advancement is key for the growth of the medical devices market. Hence, manufacturers are keen on developing and offering innovative solutions to surgeons and patients.Bio blade is an innovative ophthalmic surgical blade recommended for uncomplicated eye surgeries, with excellent sharpness and consistency for smooth and uniform incisions.

Request for a Discount on Ophthalmic Knives Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=66695

Bio blades are manufactured from highly purified stainless steel, which makes the blade hard and break-resistant, and are highly preferred by surgeons. Rise in the adoption of bio blades offers considerable opportunities to the providers of advanced ophthalmic care across the world.

Key Players Driving Global Ophthalmic Knives Market

The global ophthalmic knives market is fragmented in terms of number of players. Key players in the global ophthalmic knives market include Sidapharm, Surgical Specialties Corporation, Pfm medical ag, Alcon, Surgi Edge, Eagle Lab, Mani, Inc., Optitech Eyecare, Unique Technologies Inc., and Shah Eye Care Pvt. Ltd.

Original post:
Ophthalmic Knives Market is Expected To Increase Up to US$ 460 mn by 2027 - Downey Magazine

Read More...

Vision Care Market Poised to Expand at a Robust Pace Over 2028 – Statsflash

November 22nd, 2019 5:54 pm

Global Vision Care Market: Overview

An upcoming report on the global vision care market by TMR Research could be a valuable source of information for major stakeholders in the market. The report would offer a brilliant study of the market with its focus on market dynamics, segmentation, and geographical outreach. It could prove to be a useful guideline for players wanting to cement their position in the global vision care market.

Vision care or maintaining eye health are the major concerns globally. Vision-related diseases elevate the risk of blindness or significant vision loss. Good vision eases out daily important activities such as writing, reading, and watching. These also helps in communication, health, work, developmental learning and impacts in overall quality of life. Various factors such as chronic diseases, pollution, and unhealthy diets can affect in functioning of the eyes. Thus, plenty of products and treatments are developed to control vision related problems.

Request Brochure of Vision Care Market Report for more Industry Insights @CLICK HERE NOW

Global Vision Care Market: Trends and Opportunities

Increasing usage of laptops, tablets, PCs, and phones in day-to-day lives, growing older population, and rising number of vision-related problems are believed to be driving the global vision care market. Apart from blindness, there are various vision related problems such as astigmatism, myopia, macular edema, retinal tears, and diabetic retinopathy. Growing demand from the population aged 65+ years, increasing healthcare industry, and rapid technological advancement in eye care products are expected to boost the global vision care market.

Although, declining eye care treatment rate, product design, and brand name are also projected to hinder the growth in the global vision care market. However, growing brand awareness and paradigm shift in the consumer behavior are projected to propel the global vision care market.

Global Vision Care Market: Market Potential

Growing advent of innovative product launches is expected to fuel the global vision care market. There are several products available for vision care such as contact lens, glass lens, contact lens solution, and IOLs. The incorporation of technology in developing vision care products increase efficiency, improves quality and precision of the final product, and reduces overall cost. Increasing demand for restoring normal vision with eyeglasses or contact lenses, cost-effectiveness in using vision care products instead of LASIK eye surgery, and rising advanced medical treatment are believed to be driving the global vision care market.

Global Vision Care Market: Regional Outlook

Region wise, there is a possibility of North America to lead the global vision care market as the region has witnessed rapid development in healthcare industry. Growing population suffering from eye related disorders, rapid technological advancement, and increasing healthcare industry with advanced infrastructure could also be fueling the global vision care market. The prominent countries in this region are US and Canada. Easy availability of glass lens and innovative product launches with the help of modern technology are projected to propel the global vision care market in these countries.

Get TOC of Vision Care Market Report for more Industry Insights @CLICK HERE NOW

Global Vision Care Market: Competitive Dynamics

Some of the prominent players operating in the global vision care market areJohnson & Johnson, Valeant Pharmaceuticals, Novartis, ZEISS and The Cooper Companies.The upcoming TMR report would provide crucial information on their product offerings, market standing, and strategies for progress.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read more from the original source:
Vision Care Market Poised to Expand at a Robust Pace Over 2028 - Statsflash

Read More...

Neglected tropical diseases leave victims liable to families, says expert – ANI News

November 22nd, 2019 5:54 pm

ANI | Updated: Nov 22, 2019 06:58 IST

Abu Dhabi [UAE], Nov 21 (ANI): Neglected tropical diseases (NTDs), such as intestinal worms in children, river blindness and glaucoma, cause physical disability among the victims and make them liable to their families and societies for the rest of their lives especially in poor countries across the globe, an expert told WAM news agency."Neglected Tropical Diseases, NTDs, affect 1.5 billion people across the globe, causing massive disability. These disabled people cannot work and fully contribute to their communities," said Ellen Agler, CEO of END Fund, a non-governmental organisation working to eliminate NTDs.Diseases like intestinal worms in children hold them back from their school and cause anaemia and growth disorders; river blindness (also known as onchocerciasis) and blinding glaucoma cause blindness at an early age, which affects their ability to study and work, Agler explained in an interview on the sidelines of the Reaching the Last Mile Forum (RLMF) in Abu Dhabi on Tuesday.Therefore, these diseases make a ripple effect on education and economy of a society, she stressed.Presently, there is a funding gap of an estimated USD 300 million a year. "This is a small amount, compared to other global health needs. One of the important things about NTDs is, they can be treated for US$0.50 per person per year," she noted.Agler, from her experience of working in more than 25 countries, recalled that community health workers and teachers play a major role in treating NTDs."In many [poor] countries there are more schools than health clinics, and they are a good platform to capture children who need deworming medicine. Therefore, teachers play an incredible role in treating these diseases," she was quoted saying.Meanwhile, Agler also appreciated Crown Prince of Abu Dhabi, Sheikh Mohamed bin Zayed Al Nahyan, for taking steps in eradicating NTDs."Sheikh Mohamed bin Zayed launched the Reaching the Last Mile Fund, RLMF, two years ago in 2017," the expert said.Administered by the END Fund, RLMF is a 10-year, USD 100 million initiative launched by the Abu Dhabi Crown Prince, supported by the Bill and Melinda Gates Foundation and the UK's Department for International Development, DFID.The Forum aims to pave the way for global elimination of river blindness and Lymphatic filariasis.Caused by parasitic work, the disease leads to severe itching, skin disfigurement, and blindness among more than 197 million people in 31 countries.Studies also estimate that river blindness elimination in Africa could generate up to US$6 billion in economic benefits across the continent.More than 856 million people in 53 countries are in need of treatment for lymphatic filariasis, which is caused by the transmission of filarial parasites through mosquitoes.Lymphatic filariasis damages the lymphatic system, which causes abnormal growth of body parts called elephantiasis and can lead to disability, social stigma, and isolation.In 2018, Reaching the Last Mile Fund delivered over 13.5 million treatments for river blindness and lymphatic filariasis, and trained 76,000 health care workers to help expand treatment and outreach.The Fund is currently targeting river blindness elimination in seven countries: Mali, Senegal, Niger, Chad, Sudan, and Ethiopia in Africa, as well as in Yemen in the Middle East. (ANI)

Read more:
Neglected tropical diseases leave victims liable to families, says expert - ANI News

Read More...

SOLIRIS (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) -…

November 22nd, 2019 5:54 pm

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Japans Ministry of Health, Labour and Welfare (MHLW) has approved the extension of the current marketing authorization of SOLIRIS (eculizumab) to include the prevention of relapse in patients with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD), including neuromyelitis optica.

We are pleased that the Japanese health authorities have approved SOLIRIS as a new treatment for patients suffering from this complex and unpredictable disease, said John Orloff, M.D., Executive Vice President and Head of Research and Development at Alexion. Nearly all patients treated with SOLIRIS were relapse free at 48 weeks in the Phase 3 PREVENT study, providing new hope for Japanese patients with NMOSD and their clinicians.

NMOSD is a rare, devastating, complement-mediated disorder of the central nervous system characterized by relapses, also referred to as attacks. Each attack can result in stepwise accumulation of disability, including blindness and paralysis and sometimes premature death. NMOSD disproportionately strikes young women in the prime of their lives, with the average age of first onset at just 39 years. Previously known as Devics Disease, NMOSD is often confused with other neurological illnesses such as multiple sclerosis (MS), which can lead to delays in diagnosis and treatment with medicines that can worsen disease progression.

The understanding of NMOSD has rapidly evolved in recent years since complement activation by AQP4 antibodies was identified as an underlying cause of the disease, said Kazuo Fujihara, Professor, Fukushima Medical University, Director of the Multiple Sclerosis & Neuromyelitis Optica Center at Southern Tohoku Research Institute and a principal investigator in the PREVENT trial of SOLIRIS in anti-AQP4 antibody-positive NMOSD. With the first approved medicine for NMOSD in Japan, SOLIRIS will provide highly effective treatment to prevent future relapses in these patients.

The approval of SOLIRIS was based on comprehensive results from the Phase 3 randomized, double-blind placebo controlled PREVENT trial, which were published in The New England Journal of Medicine and a long-term extension study (ECU-NMO-302), which is still underway. In the PREVENT study, patients with NMOSD who were anti-AQP4 antibody-positive were treated with SOLIRIS (n=96) or placebo (n=47). The study met its primary endpoint of prolonging the time to first adjudicated relapse and reducing the risk of relapse. At 48 weeks, 98 percent of patients treated with SOLIRIS were relapse free compared to 63 percent of patients receiving placebo. Of the approximately one quarter of patients treated solely with SOLIRIS monotherapy, without receiving other immunosuppressive therapies, 100 percent were relapse free at 48 weeks compared to 61 percent in the placebo group. Sustained effects of SOLIRIS were observed through 144 weeks of treatment.

The safety profile of SOLIRIS was consistent with that seen for SOLIRIS in other clinical studies and real-world use in its three approved indications. The most common adverse events observed in the PREVENT study were upper respiratory tract infection (29 percent of patients in the SOLIRIS group vs. 13 percent in the placebo group), headache (23 vs. 23 percent), nasopharyngitis (21 vs. 19 percent) and nausea (17 vs. 26 percent). The serious adverse events that were reported for more than one patient in either group were pneumonia (three patients in the SOLIRIS group vs. one patient in the placebo group) and cellulitis, sepsis and urinary tract infection (two patients for each event in the SOLIRIS group vs. no patient in the placebo group). One patient receiving SOLIRIS and concomitant supportive IST died from a pulmonary empyema. The patient had an extensive history of pulmonary disease and was an active smoker. No cases of meningococcal infection were observed in the study.

SOLIRIS was approved for the treatment of NMOSD in adult patients who are anti-AQP4 antibody-positive by the U.S. Food and Drug Administration (FDA) in June 2019 and by the European Commission (EC) in August 2019. SOLIRIS received Orphan Drug Designation (ODD) for the treatment of NMOSD in the U.S., EU and Japan.

About NMOSDNMOSD is a rare and severe, autoimmune, inflammatory disorder that attacks the central nervous system (CNS), in which complement activation due to anti-aquaporin-4 (AQP4) antibodies plays a significant role in the disease process. Patients with NMOSD experience unpredictable attacks, also referred to as relapses, which can cause irreversible damage to the optic nerve and spinal cord and can lead to long-term disability. The most common symptoms of NMOSD are optic neuritis and transverse myelitis. Optic neuritis can cause visual problems including blindness; transverse myelitis can cause mobility problems including paralysis. The disease primarily affects women, often in the prime of their lives, with an average age of onset of 39 years. The prevalence of NMOSD may be more common and more severe in non-Caucasian populations worldwide.

Approximately three quarters (73%) of all patients with NMOSD have AQP4 auto-antibodies. In patients with anti-AQP4 antibody-positive NMOSD, the bodys own immune system can turn against itself to produce auto-antibodies against AQP4, a protein on certain cells in the optic nerve, brain and spinal cord that are critical for the survival of nerve cells. The binding of these anti-AQP4 auto-antibodies activates the complement cascade, another part of the immune system. Complement activation by anti-AQP4 auto-antibodies can cause destruction of vital cells in the CNS, leading to demyelination and to the death of neurons, predominantly in the spinal cord and optic nerve.

About SOLIRISSOLIRIS (eculizumab) is a first-in-class complement inhibitor that works by inhibiting the C5 protein in the terminal part of the complement cascade, a part of the immune system. The terminal complement cascade, when activated in an uncontrolled manner, plays a role in severe rare and ultra-rare disorders. SOLIRIS, an intravenously administered therapy, is approved in the U.S., EU, Japan and other countries as a treatment for adult patients with PNH and for adults and children with aHUS. SOLIRIS is not indicated for the treatment of patients with Shiga-toxin E. coli-related hemolytic uremic syndrome (STEC-HUS). In the U.S., SOLIRIS is also approved for the treatment of generalized MG (gMG) in adult patients who are anti-AChR antibody-positive and for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-AQP4 antibody-positive. In the EU, SOLIRIS is approved as the first and only treatment of refractory gMG in adults who are anti-AChR antibody-positive and for the treatment of NMOSD in adult patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease. In Japan SOLIRIS is approved for the treatment of patients with gMG who are anti-AChR antibody-positive and whose symptoms are difficult to control with high-dose intravenous immunoglobulin (IVIG) therapy or plasmapheresis (PLEX).

Important Safety Information

INDICATIONS & IMPORTANT SAFETY INFORMATION FOR SOLIRIS (eculizumab)

INDICATIONS

What is SOLIRIS?SOLIRIS is a prescription medicine called a monoclonal antibody. SOLIRIS is used to treat patients with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH). SOLIRIS is used to treat adults and children with a disease called atypical Hemolytic Uremic Syndrome (aHUS). SOLIRIS is not for use in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). SOLIRIS is used to treat adults with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. SOLIRIS is used to treat adults with a disease called neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive. It is not known if SOLIRIS is safe and effective in children with PNH, gMG, or NMOSD.

IMPORTANT SAFETY INFORMATION

SOLIRIS is a medicine that affects the immune system. SOLIRIS can lower the ability of the immune system to fight infections. SOLIRIS increases the chance of getting serious and life-threatening meningococcal infections. Meningococcal infections may quickly become life-threatening and cause death if not recognized and treated early.

Meningococcal vaccines must be received at least two weeks before the first dose of SOLIRIS if one has not already had this vaccine. If ones doctor decided that urgent treatment with SOLIRIS is needed, meningococcal vaccination should be administered as soon as possible. If one has not been vaccinated and SOLIRIS therapy must be initiated immediately, two weeks of antibiotics should also be administered with the vaccinations. If one had a meningococcal vaccine in the past, additional vaccination might be needed before starting SOLIRIS. Patients should ask their doctor if an additional meningococcal vaccination is needed. Meningococcal vaccines reduce the risk of meningococcal infection but do not prevent all meningococcal infections. Call ones doctor or get emergency medical care right away if any of these signs and symptoms of a meningococcal infection occur: headache with nausea or vomiting, headache and fever, headache with a stiff neck or stiff back, fever, fever and a rash, confusion, muscle aches with flu-like symptoms, and eyes sensitive to light. Ones doctor will provide a Patient Safety Card about the risk of meningococcal infection. Carry the card at all times during treatment and for 3 months after the last SOLIRIS dose.

SOLIRIS is only available through a program called the SOLIRIS REMS.

SOLIRIS may also increase the risk of other types of serious infections. If ones child is treated with SOLIRIS, make sure that the child receives vaccinations against Streptococcus pneumoniae and Haemophilus influenzae type b (Hib). Certain people may be at risk of serious infections with gonorrhea. Talk to the doctor about whether one is at risk for gonorrhea infection, about gonorrhea prevention, and regular testing. Certain fungal infections (Aspergillus) may also happen if one takes SOLIRIS and has a weak immune system or a low white blood cell count.

Do not receive SOLIRIS if one has a meningococcal infection, or has not been vaccinated against meningitis infection unless ones doctor decides that urgent treatment with SOLIRIS is needed.

Before one receives SOLIRIS, tell the doctor about all of the medical conditions, including if one: has an infection or fever, is pregnant or plans to become pregnant, and is breastfeeding or plans to breastfeed. It is not known if SOLIRIS will harm an unborn baby or if SOLIRIS passes into the breast milk.

Tell the doctor about all the medicines one takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. SOLIRIS and other medicines can affect each other, causing side effects. It is important that one: has all recommended vaccinations before starting SOLIRIS, receives 2 weeks of antibiotics if one immediately starts SOLIRIS, and stays up-to-date with all recommended vaccinations during treatment with SOLIRIS. Know the medications one takes and the vaccines one receives. Keep a list of them to show the doctor and pharmacist when one gets a new medicine.

If one has PNH, the doctor will need to monitor closely for at least 8 weeks after stopping SOLIRIS. Stopping treatment with SOLIRIS may cause breakdown of the red blood cells due to PNH. Symptoms or problems that can happen due to red blood cell breakdown include: drop in the number of the red blood cell count, drop in the platelet counts, confusion, kidney problems, blood clots, difficulty breathing, and chest pain. If one has aHUS, the doctor will need to monitor closely during and for at least 12 weeks after stopping treatment for signs of worsening aHUS symptoms or problems related to abnormal clotting (thrombotic microangiopathy). Symptoms or problems that can happen with abnormal clotting may include: stroke, confusion, seizure, chest pain (angina), difficulty breathing, kidney problems, swellings in arms or legs, and a drop in the platelet count. SOLIRIS can cause serious side effects including serious allergic reactions. Serious allergic reactions can happen during ones SOLIRIS infusion. Tell the doctor or nurse right away if one gets any of these symptoms during the SOLIRIS infusion: chest pain, trouble breathing or shortness of breath, swelling of the face, tongue, or throat, and feeling faint or pass out. If one has an allergic reaction to SOLIRIS, the doctor may need to infuse SOLIRIS more slowly, or stop SOLIRIS.

The most common side effects in people with PNH treated with SOLIRIS include: headache, pain or swelling of the nose or throat (nasopharyngitis), back pain, and nausea. The most common side effects in people with aHUS treated with SOLIRIS include: headache, diarrhea, high blood pressure (hypertension), common cold (upper respiratory infection), stomach-area (abdominal) pain, vomiting, pain or swelling of the nose or throat (nasopharyngitis), low red blood cell count (anemia), cough, swelling of legs or feet (peripheral edema), nausea, urinary tract infections, and fever. The most common side effects in people with gMG treated with SOLIRIS include: muscle and joint (musculoskeletal) pain. The most common side effects in people with NMOSD treated with SOLIRIS include: common cold (upper respiratory infection); pain or swelling of the nose or throat (nasopharyngitis); diarrhea; back pain; dizziness; flu like symptoms (influenza) including fever, headache, tiredness, cough, sore throat, and body aches; joint pain (arthralgia); throat irritation (pharyngitis), and bruising (contusion).

Please see the accompanying full Prescribing Information and Medication Guide for SOLIRIS, including BOXED WARNING regarding serious and life-threatening meningococcal infections.

About AlexionAlexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). In addition, the company is developing several mid-to-late-stage therapies, including a second complement inhibitor, a copper-binding agent for Wilson disease and an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases as well as several early-stage therapies, including one for light chain (AL) amyloidosis and a second anti-FcRn therapy. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. This press release and further information about Alexion can be found at: http://www.alexion.com.

[ALXN-G]

Forward-Looking StatementThis press release contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Alexion, including statements related to: the potential benefits of SOLIRIS as a treatment and prevention of relapse in adult patients with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD) and the potential impact of SOLIRIS on patients suffering from NMOSD; and that Soliris can help prevent future relapses. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ materially from those expected by these forward looking statements, including for example: the anticipated benefits of SOLIRIS for NMOSD patients may not be realized (and the results of the clinical trials may not be indicative of the results once approved for use in the European Union); results of clinical trials may not be sufficient to satisfy any other regulatory authority in order to approve SOLIRIS as a treatment for NMOSD (or they may request additional trials or additional information); results in clinical trials may not be indicative of results from later stage or larger clinical trials (or in broader patient populations); the possibility that results of clinical trials are not predictive of safety and efficacy and potency of our products (or we fail to adequately operate or manage our clinical trials) which could cause us to discontinue sales of the product (or halt trials, delay or prevent us from making regulatory approval filings or result in denial of approval of our product candidates); unexpected delays in clinical trials; unexpected concerns regarding products and product candidates that may arise from additional data or analysis obtained during clinical trials or obtained once used by patients following product approval; future product improvements may not be realized due to expense or feasibility or other factors; delays (expected or unexpected) in the time it takes regulatory agencies to review and make determinations on applications for the marketing approval of our products; inability to timely submit (or failure to submit) future applications for regulatory approval for our products and product candidates; inability to timely initiate (or failure to initiate) and complete future clinical trials due to safety issues, IRB decisions, CMC-related issues, expense or unfavorable results from earlier trials (among other reasons); our dependence on sales from Soliris, our principle product; future competition from biosimilars and novel products; decisions of regulatory authorities regarding the adequacy of our research, marketing approval or material limitations on the marketing of our products; delays or the inability to launch product candidates due to regulatory restrictions, anticipated expense or other matters; interruptions or failures in the manufacture and supply of our products and our product candidates; failure to satisfactorily address matters raised by the European Commission and other regulatory agencies regarding products and product candidates; uncertainty of long-term success in developing, licensing or acquiring other product candidates or additional indications for existing products; inability to complete acquisitions or grow the product pipeline through acquisitions (including due to failure to obtain antitrust approvals); the possibility that current rates of adoption of our products are not sustained; the adequacy of our pharmacovigilance and drug safety reporting processes; failure to protect and enforce our data, intellectual property and proprietary rights and the risks and uncertainties relating to intellectual property claims, lawsuits and challenges against us (including intellectual property lawsuits relating to Ultomiris brought by third parties and inter partes reviews of existing patents); the risk that third party payors (including governmental agencies) will not reimburse or continue to reimburse for the use of our products at acceptable rates or at all; failure to realize the benefits and potential of investments, collaborations, licenses and acquisitions; the possibility that expected tax benefits will not be realized; potential declines in sovereign credit ratings or sovereign defaults in countries where we sell our products; delay of collection or reduction in reimbursement due to adverse economic conditions or changes in government and private insurer regulations and approaches to reimbursement; uncertainties surrounding legal proceedings, company investigations and government investigations, including investigations of Alexion by the U.S. Securities and Exchange Commission (SEC) and U.S. Department of Justice; the risk that estimates regarding the number of patients with PNH, aHUS, gMG, NMOSD, HPP and LAL-D and other indications we are pursuing are inaccurate; the risks of changing foreign exchange rates; risks relating to the potential effects of the Company's restructuring; risks related to the acquisition of Syntimmune and other companies and co-development efforts; and a variety of other risks set forth from time to time in Alexion's filings with the SEC, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 and in our other filings with the SEC. Alexion disclaims any obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.

Read the original:
SOLIRIS (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) -...

Read More...

Autologous Stem Cell and Non Stem Cell Based Therapies Market Shares, Strategies, and Forecasts Analysis – Downey Magazine

November 22nd, 2019 5:53 pm

In autologous stem cell and non-stem cell based therapies, an individuals cell is cultured and then re-introduced to the donors body. Used for the treatment of various bone marrow diseases, autologous stem cell and non-stem cell based therapies allows patients to have normal bone marrow, which gets destroyed in chemotherapy. The various diseases that can be treated with the help of autologous stem cell and non-stem cell based therapies include: multiple myeloma, aplastic anemia, non-Hodgkins lymphoma, Parkinsons disease, Hodgkins lymphoma, thalassemia, and diabetes. Thus, the demand for this therapy is projected to rise over the coming years.

The report is a thorough analysis of theAutologous Stem Cell and Non-Stem Cell Based Therapies Market. Comprising an in-depth analysis of the various factors boosting and inhibiting the growth of the market, this report is a key to making profitable decisions by investing in the correct segment and sub-segment, which is anticipated to make the most progress in the future.

Request a PDF Brochure of Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4001

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Trends and Opportunities

One of the key drivers for this market is the rise in the prevalence of cancer and diabetes among people across all age groups. Moreover, the growing geriatric population is another factor, which is likely to create a heightened demand for autologous stem cell and non-stem cell based therapies. Favorable reimbursement policies across several nations are also aiding the growth of this market.

Players in the market are striving to achieve therapies that are not only safe and effective but also affordable and easy to use. Players are also investing in extensive research and development so as to speed up the treatment process of autologous stem cell and non-stem cell based therapies. While currently this treatment is quite expensive, government bodies are expected to take up initiatives and make the therapy affordable in the years to come. This is expected to drive the market in the future.

On the other hand, challenges faced by the global autologous stem cell and non-stem cell based therapies market include risks and complications associated with the therapy, such as diarrhea, hair loss, nausea, severe infections, vomiting, heart complications, and infertility.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Geographical Analysis

By geography, North America, trailed by Europe is leading in the autologous stem cell and non-stem cell based therapies market, on account of the minimization of risks associated with the therapy. Also, these therapies are highly in demand owing to their ability to treat a large number of infectious diseases. The fact that autologous stem cell and non-stem cell based therapies do not require an outside donor, makes it more convenient and less infectious. All these factors are boosting the growth of the market in North America.

Asia Pacific is projected to show the most promising growth in the years to come with high demand from China, Vietnam, Malaysia, and India. The demand is expected to be high as autologous stem cell and non-stem cell based therapies help in the effective treatment of cardiovascular diseases. Sophisticated healthcare infrastructure and favorable tax and reimbursement policies are also expected to aid the growth of the Asia Pacific autologous stem cell and non-stem cell based therapies market.

Request for a Discount on Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=4001

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Companies Mentioned

Some of the leading players operating in the autologous stem cell and non-stem cell based therapies market are Fibrocell Science, Inc., Aastrom Biosciences, Dendreon Corporation, NeoStem, Inc., BrainStorm Cell Therapeutics, Regeneus Ltd., and Genzyme Corporation.

Read more here:
Autologous Stem Cell and Non Stem Cell Based Therapies Market Shares, Strategies, and Forecasts Analysis - Downey Magazine

Read More...

Missing Link To Longevity Discovered In The Plant Kingdom – Texas A&M University

November 22nd, 2019 5:52 pm

lead researcher Dorothy Shippen, Ph.D., (left), graduate student Jiarui Song, first author (center) and postdoctoral fellow Claudia Castillo-Gonzlez, second author (right).

Texas A&M AgriLife

A breakthrough discovery by Texas A&M University and Arizona State University professors could provide a key component in understanding the human aging process and even aid in the battle against cancer.

Dorothy Shippen, Ph.D., is a University Distinguished Professor and Regents Fellow in Texas A&MsDepartment of Biochemistry and Biophysicsand withTexas A&M AgriLife Research, College Station.

Shippen co-led a study with Julian Chen, Ph.D., professor of biochemistry, Arizona State Universitys School of Molecular Sciences. First author, Jiarui Song, is a graduate student with Shippen.

Their study, The conserved structure of plant telomerase RNA provides the missing link for an evolutionary pathway from ciliates to humans, is being published in the Proceedings of the National Academy of Sciences.

Our discovery of this key component of the telomerase enzyme in the plant kingdom provides an evolutionary bridge, and a novel path forward, for understanding how humans keep their DNA safe and enable cells to divide indefinitely, Shippen said.

Moreover, since plants often evolve interesting solutions to fundamental biological problems, some of the lessons we learn from plant telomerases may provide new ways for addressing stem cell disease and cancer.

We found a core component of the telomerase enzyme that had been missing all these years, Shippen said. And by finding this component in plants, we not only learn new lessons about how telomerase evolved, but we also open the door to learn new things about the human enzyme.

Back in 2001, Shippen published a paper outlining the discovery of the catalytic subunit of the telomerase enzyme from plants. The catalytic component is one of two absolutely critical parts of the enzyme, and it is now very well understood.

However, the second component, the RNA subunit, that provides the enzyme with information about what to do with chromosome ends, was missing.

Our new discovery is the RNA subunit of telomerase from the plant kingdom. In the plant telomerase RNA, we can now see the signatures for the human telomerase and telomerase from simple organisms like bakers yeast and the microbes in pond scum.

The missing piece always was this subunit. Now that we have found the correct one, its opened up a lot of interesting insights.

Plants have different, innovative solutions to so many biological challenges, and insight into these may provide important clues on how human telomerase is regulated, she said.

We can study the telomerase enzyme more deeply and see so much more now, and it can help us understand how the human enzyme is going to work. It really is this missing middle ground.

In the 1930s, Barbara McClintockwas studying the behavior of chromosomes in maize and was one of the first scientists to appreciate the importance of telomeres.The Shippen Labin the 1990s followed up on the pioneering work of McClintock in model plant systems and discovered the telomerase enzyme, which is required for maintaining these structures on the ends of chromosomes.

Shippens longtime studies on telomerase, which play an essential role in chromosome stability and cell proliferation capacity, has led her to be considered the worlds expert in plant telomere research.

The telomere is like a biological clock. There is a certain amount of telomeric DNA at the end of chromosomes. As cells divide, they lose part of this DNA.

She has likened telomeres to the plastic tip on the end of a shoelace they form a protective seal on the ends of chromosomes in plants and animals. Like the plastic tip that wears out, allowing the shoelace to fray and become hard to use, so does the telomere break down in most cells in the human body over time.

The telomerase enzyme is capable of replenishing the lost DNA at chromosome ends and it is available in cells that are immortal, Shippen said. Its active in the stem cells, but not active in other places of the body normally.

Theres a whole connection between immortality and telomerase that needs to be studied.

Why is telomerase only active in stem cells, turned off in other cells and why does it get reactivated in cancer cells? Shippen said. Weve learned a lot about the human telomerase from pond scum, but plants can provide still more clues because their growth and development is so plastic. If you cut a flower from a plant growing in the garden, it will grow another flower. But if you cut off the tip of your finger, you wont be growing a new one.

Its a big mystery.

But Shippen said the plant telomerase is still very similar to the human telomerase.

It is remarkable that even in plants, telomerase is active only in cells that need to divide many times.

She expects that what is learned in the plant system will ultimately be translatable and have significant impact in human medicine.

See the original post:
Missing Link To Longevity Discovered In The Plant Kingdom - Texas A&M University

Read More...

The New Face of Longevity: Dwayne Clark’s Solution to America’s Silver Tsunami Crisis and How Living on Stolen Potatoes Made It All Possible -…

November 22nd, 2019 5:52 pm

November21, 201910 min read

Opinions expressed by Entrepreneur contributors are their own.

If you ask Dwayne Clark, founder and CEO of the senior care company Aegis Living, what he is most thankful for in life, he will unabashedly tell you growing up poor.

For Clark, a childhood spent in poverty instilled a compassion-first mentality and a burning desire to help others lead lives of dignity.

Today, Clark is seen as a change-maker in his industry. Aegis opened its 32nd location this year and has eight more facilities in development. The company is on track to have operating revenues of over $300 million in 2020, with real estate holdings approaching $3 billion.

Clark is the youngest of four children raised by a single mother in Walla Walla, Washington. When he was 16, his mother told him they were completely broke and had no money for food.

The youngest of four children, Clark was raised by a single mother who struggled to feed her family.

Image credit: Dwayne Clark

To feed her family, she made potato soup from a bag of potatoes shed stolen from the restaurant where she worked as a line cook. She vowed to replace the potatoes when she had money again. While Clark felt powerless to help his mother, he remembers being in awe of her strength and resilience.

My background truly is a gift to me, he says. It helps me relate to the dishwasher and has given me an affinity for struggling immigrants, for the poor kid, whoever needs help. If I hadnt grown up knowing what being hungry is really like, I would not have created the business I run today.

By the time he was 26 years old, Clark had worked his way up from a correctional officer to shift commander at Washington States Department of Corrections. He was good at it, but he hated the job. He wanted to go back to college (hed dropped out in his junior year) and then to law school, but his sister interrupted these plans with a call out of the blue. She insisted he read a new study about aging in America.

This was before we had the internet and I could just pull it up on a computer; so I went to the library to look up the study, says Clark. It was around 400 pages. I didnt particularly want to read it, but it seemed important to her. So I read the whole thing and realized there was a silver tsunami coming fast.

He learned that life expectancy was on the rise and the elderly population was expected to double. His takeaway: eldercare was going to be a booming industry. Clarks sister was on the advisory board of one of Leisure Cares communities, so he asked her to help get him an interview.

I didn't want this to be a courtesy 10- to 15-minute interview. So when they asked if I could come in for an interview that next week, I said I could come in 30 days, says Dwayne. I wanted to do my research on the company, their competitors, and the industry. I wanted to be the best interview theyd had in 10 years.

Thirty days later, Dwayne went in for the interview, and, as expected, they asked a few cursory questions, spent no more than 10 minutes with him, and thanked him for coming in. Before they could shoo him out the door, Dwayne reached into his backpack and pulled out a three-ring binder and dropped it on the desk in front of him.

Id like to talk to you about where I think the aging industry is going and how I think I could contribute, he told them. Clark says they spent the next 90 minutes going over his manual, and they made him a job offer within the week.

Leisure Care hired Clark as the marketing director in Colorado. Forty-five days later he was put in a manager training program, and two years later he was named VP of Operations.

At age 33, Clark was recruited by Sunrise Senior Living, which would the biggest senior housing company in the world. In less than five years he helped grow Sunrise from an $18 million company to a company with a $3 billion market cap.

Despite his seemingly overnight success in the eldercare industry, Clark wasnt satisfied working for a public company. He decided to quit and make his own way.

It wasnt in my personality, and I didnt like what Wall Street did to the culture of the companies, says Dwayne. I thought I needed to just do it on my own.

You need a significant amount of money to do well in the senior care industry, and I dont mean $10 million; I mean tens of millions of dollars, he says. Today you would need $150 million to start a company like Aegis.

Dwayne spent much of 1996 looking for partners and capital sources and eventually found the right person: a developer in California named Bill Gallaher, whom Clark had built a relationship with during his time at Sunrise.

Together they founded Aegis, were able to raise $10 million, and built their first property in Pleasant Hill, California, in 1998. But it wasnt all smooth sailing.

I underestimated just how capital intensive the process was, says Clark. We burned through that first $10 million in six to nine months.

After two more rounds of capital financing, which yielded another $12.5 million, Gallaher called and told him they were out of money. By this point, Clark had exhausted all his resources except his sons college fund.

My son had just committed to UCLA, his dream school, says Clark. I needed the college money to cover payroll or Aegis could not stay afloat. I had to go to my son and have a tough conversation. I said, You know, that in-state tuition at the University of Washington looks really good.

Thankfully, his son understood and never felt bitter about the decision to abandon UCLA. Clark credits the college fund for saving the company.

In 2007, Clark says he bought out Gallaher due to a difference in philosophies. He took full control of Aegis and set out to grow it into the premier assisted living community on the West Coast.

As the company expanded, Clark became an expert on how to care for people with Alzheimers and dementia. He believed hed learned everything there was to know about how to manage this type of care facility until the day he received a massive blow that challenged him as a CEO and son: his mother was diagnosed with Alzheimers.

Image credit: Dwayne Clark

Imagine the feeling of being the guy leading the industry in this type of care but I couldnt help my own mother, admits Dwayne.

She moved into one of his memory-care communities, and Clark began to have a major shift in perspective. It was a game changer, he says.

His mother loved music; so Clark read studies on the positive effects of music on patients with dementia and Alzheimers and expanded the music programs in his Alzheimers wing.

She also loved doing her hair and make-up, which became harder as her illness worsened. As a result, Clark brought traveling salons to his senior health communities to give all the residents makeovers. This started a long list of improvements throughout his facilities that werent always good for his companys bottom line but he believes improved the lives of the residents. Clark says he created hundreds of longevity aids, including aromatherapy to improve mental clarity, spring-loaded chairs to allow seniors to stand without assistance, and shorter hallways to facilitate walking.

Clark also took action to create a culture where employees feel genuinely invested in and cared about.

I want to be an employee-first company because I truly believe culture is everything, says Clark. We are a service-oriented company that aims to do our part in treating the Alzheimers epidemic by serving the high-risk communities of senior health.

Clark created a program called E.P.I.C. (Empowering People Inspiring Consciousness) to transform Aegis Livings annual meeting from a traditional year-end review to a three-day celebration of the human spirit. It is a seminar for self-improvement with the primary agenda to ignite personal development among the employees. E.P.I.C. attracts celebrities like Michael J. Fox, Carlos Santana, and Dr. Deepak Chopra to teach and inspire his employees.

Clark says one of his lifelong obsessions has been the pursuit of health understanding it and attaining it. As a young adult, he lost sight of that passion and burned the proverbial candle at both ends. He worked long hours, lived on a junk-food diet, partied late into the night, and slept very little.

Everything came to a head one Labor Day weekend with his wife, when he began to experience the most acute abdominal pain of his life. It was so bad that he ended up in the hospital where he was diagnosed with severe gastritis.

Clark says the experience was a wake-up call. Hed learned so much caring for people well into their 100s, but ironically, hed never consciously applied those lessons to himself.

My health crisis inspired me to seek out longevity, study it, achieve more of it, and share my findings with a broader audience, says Clark. While Id been living and breathing questions about the health and longevity of my Aegis residents, Id separated myself from what Id learned. Overnight, my commitment changed.

Dwayne became a longevity explorer, traveling to over 80 countries to interview hundreds of people on what it means to age well into their 80s, 90s and 100s. His obsession with health and longevity led him on a journey of research into finding every conceivable way to live a more vibrant, healthier, and more fulfilled life.

In his latest book, 30 Summers More, Dwayne takes what he has learned about longevity by caring for more than 60,000 residents and writes a new plan for aging in America. He challenges the status quo for people over age 60, using the wisdom of Aegis residents.

Clark, far right, with former Secretary of State Hilary Clinton, former President Bill Clinton, and Clarks wife, Terese, after a lunch where the couples discussed politics, business, and longevity.

Image credit: Dwayne Clark

Hes also taken an interest in exploring what makes successful people tick, and Clarks recently launched podcast, Walk This Way, discusses the journey of CEOs, athletes, and celebrities and how they made their way to hit mega-success by not following the traditional path.

Clarks own path was no doubt untraditional.

I have never had a woe is me mentality or seen my background as a drawback, says Clark. Entrepreneurs share one thing: theyre trying to run as fast as they can away from poverty. It creates rocket fuel for them to be successful.

Follow Dwayne Clark on Instagram, Facebook, and LinkedIn, or visit his website.

See the original post:
The New Face of Longevity: Dwayne Clark's Solution to America's Silver Tsunami Crisis and How Living on Stolen Potatoes Made It All Possible -...

Read More...

Longevity Project explores the nuanced implications of longer life – PRNewswire

November 22nd, 2019 5:52 pm

WASHINGTON, Nov. 19, 2019 /PRNewswire/ -- As longer life expectancy brings about substantial changes in the make-up of American society, Americans are still grappling with the implications of longer life on how we work, live and learn, according to a poll fielded by the Longevity Project, a new initiative developed in collaboration with the Stanford Center on Longevity (SCL). The mission of the Longevity Project is to generate research and foster public dialogue on the far-reaching impact of increased longevity.

Some key results of the Longevity Project Morning Consult poll include:

By 2034, Americans over the age of 65 will outnumber children under 18 for the first time in history a change more frequently viewed as a negative outcome than a positive one.

And as people over the age of 55 are poised to become the largest segment of the U.S. workforce, nearly a quarter (23%) of Americans think the retirement age should be lowered to make room for younger workers.

"With Americans living longer and healthier, we have a unique opportunity to reimagine healthy, successful century long lives," said Laura Carstensen, Professor of Psychology at Stanford and the founding director of SCL. "But we can't achieve what we can't imagine, and we are pleased to help launch this initiative to foster public understanding and engagement on longevity."

Through research, conferences and events at Stanford and around the country, the Longevity Project will engage with government and business leaders on the policies and methods for supporting longer life. Conferences will include the Century Summit and Longevity Next, the first longevity conference focused on engaging millennials and Generation X about the implications of longer life.

"We are proud to work with a growing coalition of organizations including the Stanford Center on Longevity, the Urban Institute, Morning Consult, the National Academy of Medicine, and a group of forward thinking companies comprised of Principal Financial Group, Wells Fargo, and Instructure to launch this important initiative, said Ken Stern, co-chair of the Longevity Project."

The project's first poll underscores a disconnect between public perceptions of aging and the real influence of longer lifespan. A decade ago, a Pew Research Center poll put the beginning of "old age" at 68. The Longevity Project's respondents pegged the answer at a younger age, 66 -- a surprising change in an era in which many people in their 60s and 70s continue to play a significant role in public life.

Other key findings of the Longevity Project Morning Consult poll include:

View the full research findings and additional project information at http://www.longevity-project.com.

The Longevity Project, in partnership with Morning Consult, will release a larger study of longevity issues in January, and will be convening multiple forums in the coming months to explore the best approaches to promoting an effective and beneficial longer life.

Contact; Kaila Lewis kaila.lewis@palisadesmv.com443-433-6113

SOURCE Longevity Project

https://www.longevity-project.com

Read the original here:
Longevity Project explores the nuanced implications of longer life - PRNewswire

Read More...

2nd Annual Innovation Summit Focuses on Needs of Older Adults and Longevity Economy – PRNewswire

November 22nd, 2019 5:52 pm

WASHINGTON, Nov. 20, 2019 /PRNewswire/ -- The Washington Innovation in Longevity Summit, produced by Mary Furlong & Associates and the Centre for Aging + Brain Health Innovation, kicks off its second annual event on December 9th & 10th at the National Press Club. The successful inaugural event featured government agencies, nonprofits, investors, thought leaders in aging, media, and private companies focused on the needs of older adults and the burgeoning longevity economy.

Keynote speakers for the 2019 Summit include Nancy LeaMond, Executive Vice President, Chief Advocacy and Engagement Officer for AARP; and George Vradenburg, Co-founder and Chairman for UsAgainstAlzheimer's.

Jean Accius, PhD, Senior Vice President, AARP Thought Leadership and International Affairs, AARP International, and Jim Firman, EdD, President and CEO, National Council on Aging (NCOA)will open the Summit to share their unique perspectives on the unmet needs and market opportunities in serving the needs of millions of older people in the US and globally.The two-day summit focuses on the themes of Mobility, Money, Memory, Military and Media.

"Last year's Summit in Washington surpassed our expectations in terms of thought leadership, attendees, and the partnerships that were created," said Mary Furlong, Executive Producer and CEO of Mary Furlong & Associates. "We are excited to bring the Washington Innovation in Longevity Summit to our nation's capital. Our goal is to foster a learning community and network for entrepreneurs, investors, regulators, NGOs and the media, all focused on the growth of the longevity economy and serving the needs of older adults. This conference is the epicenter."

The Washington Innovation in Longevity Summit Day 1 Agenda focuses on the collaborative power of nonprofits, media, and government regulators, working in concert with entrepreneurs and investors. Day 2 is dedicated to global health partnerships in brain health, understanding go to market strategies worldwide, and helping entrepreneurs from other countries navigate the U.S. and Canadian markets.

The full agenda and summit details are here. Summit registration is available here. Key sponsors for the Summit include:

Platinum: AARP, Center for Aging + Brain Health InnovationGold: Ageless Innovation, CareLinx, Sodexo, Thrive Alliance, Posit Science

About Mary Furlong & AssociatesFor 17 years, Mary Furlong & Associates (MFA), headquartered in the San Francisco Bay area, has developed strategies for marketing and business development for companies focused on opportunities with the senior and baby boomer markets and the longevity economy. Dr. Furlong is the executive producer of three conferences annually: What's Next Boomer Business Summit, Silicon Valley Boomer Venture Summit, and Washington Innovation in Longevity Summit. She also co-produces What's Next Canada and is scheduled to add a fourth conference in Paris, France, focused on international aging.

INFORMATION:Ben Adkins 229649@email4pr.com502.619.4267

SOURCE Mary Furlong & Associates

http://www.maryfurlong.com

More:
2nd Annual Innovation Summit Focuses on Needs of Older Adults and Longevity Economy - PRNewswire

Read More...

How to live longer: Five diet tips to prevent disease and boost life expectancy – Express

November 22nd, 2019 5:52 pm

Long life expectancy can be achieved through eating the right food and drink. Some foods have been found to have a positive impact on blood pressure, inflammation, blood sugar and heart health, while others have been found to increase the risk of serious health conditions developing.

While genes play a role in life expectancy, environmental factors like diet are key.

Here are five diet changes recommended by experts to help keep health in check and achieve longevity.

Both drinks have been found to decrease the risk of chronic disease.

The polyphenols and catechins found in green tea may decrease a persons risk of cancer, diabetes and heart disease.

READ MORE:Prostate cancer: How you sleep may increase risk of developing the deadly disease

And coffee has been linked to a lower risk of type 2 diabetes, heart disease, certain cancers and brain ailments like Alzheimers disease.

Studies have also suggested both coffee and tea drinkers benefits from a 20 to 30 percent lower risk of early disease compared to non-drinkers.

But the NHS does advises: It's fine to drink tea and coffee as part of a balanced diet.

If you drink tea or coffee with sugar or you have flavoured syrups in your coffee-shop drinks, you could be unwittingly damaging your teeth and adding unhelpful calories to your diet.

DON'T MISS

A number of studies have shown nuts have beneficial effects on heart disease, high blood pressure, inflammation, diabetes and belly fat levels.

One study found participants who consumed at least three servings of nuts per week had a 39 percent lower risk of premature death.

Turmeric is renowned for its anti-inflammatory properties.

Curcumin, found in turmeric, is believed to give the yellow spice its health properties, and studies have linked it to improved brain function, lower risk of heart disease and even cancer prevention.

Curcumin has also been linked to an increased lifespan in both insects and mice.

Many studies have linked a plat-rich diet to a lower risk of premature death, as well as a reduced risk of cancer, metabolic syndrome, heart disease, depression and brain deterioration.

Plant foods are believed to hold such properties because of their nutrients, antioxidants, polyphenols carotenoids, folate and vitamin C.

Several studies have linked vegetarian and vegan diets, which involve higher plant food consumption, with a 12 to 15 percent lower risk of premature death.

Research has also suggested the risk of premature death and certain diseases increases with greater meat consumption. https://www.ncbi.nlm.nih.gov/pubmed/19307518

Heavy alcohol consumption has been linked to liver, heart and pancreatic disease, as well as an overall increased risk of early death.

But moderate consumption has been associated with a reduced risk of developing several diseases, as well as a 17 to 18 percent decreased risk of premature death.

The results of a 29-year study showed men who preferred wine were 34 percent less likely to die early than those who preferred beer or spirits.

Men and women are advised not to drink more than 14 units of alcohol a week on a regular basis.

Drinking should also be spread over three or more days if you regularly drink as much as 14 units a week.

The rest is here:
How to live longer: Five diet tips to prevent disease and boost life expectancy - Express

Read More...

On British royalty and the longevity of the institution – Hurriyet Daily News

November 22nd, 2019 5:52 pm

When I moved to England in the late 70s, the first thing that struck me was the popularity of the royal family. I was there when Queen Elizabeth II celebrated her Silver Jubilee in 1977, after 25 years on the throne.

For a young married woman and a mother who had to take up the duties of a monarch at the age of just 25, this was a difficult task. But she performed well and won the approval of the society still recovering after the traumas of the Second World War. A young queen became a symbol of unity and optimism for the future.

Millions of special jubilee mugs with the picture of Elizabeth II were distributed to the schoolchildren all over the country who proudly brought them home to decorate their bedrooms. Coming from Greece where royalty was something of an anathema, synonymous with continuous interference in the democratic will of the people, I was surprised. In Greece, by then, we had finished with a nasty period of military rule and a long period of the monarchy.

I had difficulty in explaining that unchallenged respect across the whole political spectrum towards the British monarchy. In vain, I tried opening the subject to my British friends about their antiquated hereditary class system. The standard answer I received was that the queen symbolizes the nation and our cultural and historic continuation and that the British monarchy is like our national flag.

No one would have imagined, though, that the certainty that the British royal family is a rock-hard institution to last forever would have been turned upside down, just a few years later.

Marking her 40th anniversary on the British throne, Elizabeth II looked back on that year as an annus horribilis (a terrible year). Her second son, Prince Andrew, divorced from his wife following a series of scandals exposed by British tabloids.

Her daughter, Anne divorced, and her daughter-in-law Princess Diana published Her True Story, revealing her husband Prince Charles infidelity with Camilla, who was married to another man at the time. She now is Charles wife. Everything was overexposed in the media. As if all that was not enough, a terrible fire nearly destroyed the historic Windsor Castle, the official residence of the queen. The year ended as badly as it started.

Prince Charles, heir to the throne, separated from his wife, Princess Diana. That terrible year caused a grave blow to the image of the British monarchy, and I remember that some friends, whose children had kept the queens silver jubilee mugs as precious memorabilia, had second thoughts about the usefulness of the institution.

By now, Elizabeth II, who was born in 1926, has celebrated several more anniversaries. In 2002, her Golden Jubilee for half a century on the throne, in 2012 the Diamond Jubilee for the 60th year on the throne and the Sapphire Jubilee in 2017 for the 65th year on the throne. Already preparations have started for the Platinum Jubilee in 2023 for the 70th year by which the queen will be 96 years old.

The queen may indeed celebrate her Platinum Jubilee. But will the British monarch last that long? Todays Britain is very different from what it was even a few years ago. Polarization has split the society with the Brexit affair being the latest symptom. Traditions and institutions are at stake or are being discredited. Parliament, government and British political parties are not having good days.

So, when the terrible story about the Duke of Yorks association with the late convicted pedophile Jeffrey Epstein hit the news, the reaction of the British media was as if nothing had changed since 1992. The duke of York, the second royal son, was labeled as outcast, and the press said that the palace is in crisis.

Unlike 1992, this time, the palace establishment who consults the British monarchs on what to do in moments of crisis reacted speedily. The duke was forced to step back from public life for the foreseeable future, which is expected to be quite long. Still, is this affair going to shake the trust in the British monarchy?

Probably not, at least for as long as the strong-willed Queen remains at the helm. Figures confirm that. According to last years official poll, seven out of 10 Britons support having a monarchy, and 62 percent believe that Britain will have a hereditary monarchy in 100 years.

That was why, perhaps, Boris Johnson in this weeks TV debate with Jeremy Corbyn, stated that the royal family is beyond reproach.

Read the original here:
On British royalty and the longevity of the institution - Hurriyet Daily News

Read More...

LeBron’s triple-double record a testament to longevity, versatility – The Athletic

November 22nd, 2019 5:52 pm

LOS ANGELES LeBron James was trying to figure out how impressed he should be by his latest feat. With 25 points, 11 rebounds and 10 assists against the Thunder, he became the first player in NBA history to record a triple-double against all 30 teams.

I really dont know what to really think about it, he said. Its a pretty cool stat to know. Im glad it happened in a win.

Magic never did that. Neither did the Big O. But that had more to do with era than anything. They played in a pre-expansion NBA. Pace has picked up. Triple-doubles are commonplace. Russell Westbrook is stuck at 29 teams, but he spent his whole career before this season in Oklahoma City and is a virtual lock to join James in short order.

[ Listen to The Forum Club for more Lakers coverage ]

But then again, James achieved the record a month before his 35th birthday, just shy of 15 years since his first triple-double. That came on Jan.

Read the original:
LeBron's triple-double record a testament to longevity, versatility - The Athletic

Read More...

Red Angus winner comes from long line of longevity genes – Western Producer

November 22nd, 2019 5:52 pm

EDMONTON The public face of Cinder Angus is changing from one generation to the next.

With eight head at Farmfair International, 16-year-old Brynne Yoder led out the grand champion Red Angus female with Red Cinder Freyja 29E.

A home-raised cow registered in Yoders name, it is owned with Brian and Sherrie McKenzie of Brylor Ranch at Pincher Creek, Alta.

She is out of an 18-year-old dam, Brynne said.

Nicknamed Tude, her daughters have the same longevity.

She produces some of our most elite females. She has got a beautiful disposition and she raises some of our best calves every year, Yoder said.

Freyja 29E made it to the Supreme at Farmfair for the second year in a row, and Yoder entered her at Summer Synergy in Olds, Alta., where she was grand champion Red Angus. This female has also been recognized at Canadian Western Agribition and the First Lady Classic.

She has been one heck of a marketing strategy for us, she said.

Well spoken and friendly, Yoder admits her favourite part of the business is showing cattle over the other skills she has learned such as marketing and judging.

I love to show more, she said.

I would rather not stand and talk in front of a bunch of people. I like the quiet. There is more of an adrenalin rush to show cattle.

She has made time to play competitive fastball, but working on the farm with her parents, Brad and Nicoll, is her first love. To make time for farm work, she and her sister, Tavianne, are home schooled. Her goal is to attend a post-secondary school on a livestock judging scholarship in the United States.

The rest is here:
Red Angus winner comes from long line of longevity genes - Western Producer

Read More...

Why Ikarian honey could be the key to longevity – Greek City Times

November 22nd, 2019 5:52 pm

In Ikaria honey is used to treat everything from wounds to stomach issues, influenza, and the common cold. Ikarians start their day with a simple spoonful of raw local honey, which has a high antioxidant level. This may reduce inflammation and also contains amino acids and vitamin C which are known to speed the growth of healthy tissue in the body.

This famous Greek island is a part of Blue Zones a name given to 5 places in the world- Ikaria, Sardinia in Italy, Okinawa of Japan, Nicoya of Costa Rica and Loma Linda of California, USA, whose inhabitants surpass the life expectancy and reach over the age of 90 years.

A new television report by CBS has taken a close look at whyIkarian honey could be one of the main keys as to why the locals here keep healthy and strong well into old age.

Up the winding mountain roads of this isolated isle, youre likely to notice brightly-painted boxes dotting the landscape. And whats happening inside those boxes is generating some buzz: Bees busy making a rare honey that locals believe is one of the secrets to a long life, notes CBS.

Ikarian beekeeper Andoni Karimalis explained to CBS correspondent Jonathan Vigliotti that people on the island have been eating the honey for generations, to keep healthy and strong well into old age.

At work in her weaving studio, 109-year-old Yiayia Ioanna from Ikaria agrees there is something special about it.

So does 87-year-old-beekeeper Giorgos Stenos. He eats the honey every single day.

For centuries humans have valued honey for its medicinal properties. And in Ikaria, known in ancient times as the healing island, the honey is different from that found on most supermarket shelves.

As a result, the pollen and nectar collected by the bees are free of chemicals and pesticides normally found in commercial or private farming. And unlike most honey sold in the other parts of the world, Ikarian honey is also unheated, unfiltered, and unpasteurized all processes which can destroy the natural vitamins and minerals.

Although this has been one of Ikarias best-kept secrets, after the CBS report aired live on American television, there has been a huge response with people all over the world wanting to get their hands on some on this Ikarian gem!

Read the original:
Why Ikarian honey could be the key to longevity - Greek City Times

Read More...

When longevity is the biggest achievement: on Shinzo Abe – The Hindu

November 22nd, 2019 5:52 pm

On November 20, Shinzo Abe will become the longest- serving Prime Minister of Japan, overtaking Taro Katsuras record of 2,886 days in office.

Mr. Abe has been in power for two different spells: a short-lived one, between July 2006 and September 2007, and the current stretch since 2012. Over the last seven years, he has brought stability to a political landscape that had been fractured, honing the image of a strong, conservative leader readying Japan for a newly muscular role in a shifting geopolitical landscape.

Mr. Abe has steered the economy out of deflation and decline, if not into growth. He has presided over a significant increase in the countrys military capabilities and attempted to expand Japans strategic options beyond its traditional reliance on the United States.

And yet, his legacy might not be as long-lasting as his time in office. Critics say the only reason Mr. Abe is still in power is because of a weak and uninspiring Opposition. In other words, the TINA (there is no alternative) factor that voters around the world are all too familiar with.

When Mr. Abe returned to power in 2012, Japan had been through five Prime Ministers in as many years. His immediate order of business was implementing a set of economic reforms to stimulate the economy, popularly dubbed Abenomics. The three pillars of this stimulus included monetary easing, fiscal spending and deregulation to promote private investment. He also vowed to bring more women into the workforce, an attempt nicknamed womenomics. More recently, Mr. Abe has reinvented Japan, from a recalcitrant participant in trade liberalisation to a leader of the Trans-Pacific Partnership bloc, after the U.S. withdrew from it in 2017.

Under him, Japan has boosted defence spending and enhanced its ability to project power outside of its borders. In a historic shift in 2014, Mr. Abes government reinterpreted (without amending) the Constitution to permit Japanese troops to fight overseas for the first time since the Second World War. A five-year defence programme announced in 2018 allocated 25.5 trillion yen ($233.7 billion) in spending, a 6.4% rise over the previous five years.

On the diplomatic front, Mr. Abe has reached out to traditional partners like the U.S. (he was the first foreign leader to meet with Donald Trump after the Presidents election), while keeping ties with rival China on an even keel. Mr. Abe made an official visit to Beijing last October (the first such visit in nearly seven years) and President Xi Jinping is expected in Japan next year. For Japan, it has been a difficult balancing act, to avoid excessive dependence on the U.S., while anticipating the dangers associated with a more assertive China. Mr. Abe has demonstrated considerable tactical pragmatism in walking this tightrope.

Mr. Abe has also reached out to strengthen alliances with regional powers like India and floated the idea of a Free and Open Indo-Pacific for which he has gained the backing, to varying degrees, of the U.S., Australia and India.

But, despite this smorgasbord of initiatives, Mr. Abes tenure has not been entirely rosy. The Japanese economy remains limp and Japanese corporations have so far proved unable to transform themselves into 21st century technology leaders. Though, during his tenure, Japan has benefited from periods of economic growth and low unemployment, the country remains mired in a slow-growth, high-debt deflationary trap. The government recently downgraded its 2019 growth forecast to 0.9% from an earlier prediction of 1.3%.

Domestically, Mr. Abes vision of a less pacifist Japan remains deeply contested. His most cherished policy goal is the amendment of Article 9 in the Constitution: the clause that restricts Japans ability to maintain a military deterrent. But it is looking no closer to fulfilment than it did at the beginning of his reign. The Prime Minister wants to write the existence of Japans Self-Defense Forces, as the military is known, into Article 9, giving constitutional standing to de facto reality. However, a survey conducted by the Asahi Shimbun newspaper earlier this year showed that 64% of respondents opposed even this modest revision. While Mr. Abe continues to reiterate his pledge to push through the revision by 2020, it is looking increasingly unlikely that he will prove successful.

It is also not clear how effectively, or if at all, Japan can meet the challenge of Chinas increasing heft. Relations with neighbour and potential ally, South Korea, are worse than ever. Under Mr. Abe, Japan has made little progress in facing up to its historical responsibility for the widespread atrocities of the Japanese Imperial Army in the Second World War. The recent deterioration in relations with Seoul were prompted by unresolved grievances involving Koreans who were forced to work in Japans mines and factories during the war, as well as comfort women who were made to service the militarys brothels. Far from helping heal the historical wounds inflicted by Japan, Mr. Abes nationalistic stance is seen as unrepentant at best and provocative at worst.

Finally, for all his cosying up to the U.S. President, Mr. Abe has failed to insulate Japan from Mr. Trumps transactional approach to international relations. The U.S. administration has recently asked Tokyo to pay roughly four times as much as it currently does to offset the costs of stationing American troops in Japan. The White House also threatened Japan with punitive tariffs on Japanese vehicles even as it was negotiating a bilateral trade deal with Tokyo. The administration had earlier raised tariffs on Japanese steel and aluminium.

Barring any major upheavals, Mr. Abes long reign will come to an end in September 2021 when his term as leader of the Liberal Democratic Party finishes. At the current juncture it looks as though he will get a pass in the history books, though not with distinction. A for longevity, but a B, at most, for everything else.

Pallavi Aiyar is a writer and journalist based in Tokyo

You have reached your limit for free articles this month.

Register to The Hindu for free and get unlimited access for 30 days.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Read the rest here:
When longevity is the biggest achievement: on Shinzo Abe - The Hindu

Read More...

Staring At Screens All Day Hurts More Than Just Eyesight. Here’s What To Do To Keep Your Vision Healthy – Colorado Public Radio

November 22nd, 2019 5:51 pm

Since 1971, the incidences of nearsightedness in the U.S. have nearly doubled, accounting for almost half the population.

But parents and eye doctors are seeing more than just nearsightedness in kids and teens today. The culprit? Most likely digital screens.

Teens spend, on average, seven hours a day on their phones, tablets and computers. For a tween, ages 8-13, its a little less, at 5 hours a day, according to a survey by Common Sense Media, which has been tracking this since 2003.

Ive always wondered how staring into a little screen for hours affects eyesight, Victoria Leibman said. I have two teenage daughters that are active in school sports and other activities in addition to a lot of homework. This has limited their time on social media.

Leibman reached out to CPR News after reading parts of Teens Under Stress, CPRs in-depth series on teens in Colorado. The first package focused on phones the way kids use them, the impacts on their brains and how teens can use their phones more responsibly.

Dr. Barbara Horn, president of the American Optometric Association, said kids are staring at screens for extended periods of time both in the classroom and at home.

Everybody needs to know, but children especially, that staring at a screen for too long can cause you to get headaches and eye strain, Horn said. You may not be blinking properly so your eyes may get dry there are a number of things that can occur when youre using a device for too long.

That eye strain can also impact young people in the classroom, said Dr. Tara DeRose, a pediatric optometrist at the Mountain Vista Eyecare and Dry Eye Center in Littleton, CO.

Theyre getting fatigued by the end of the day and that oftentimes correlates into them avoiding reading or avoiding doing homework because theyve just been focusing and straining all day long, DeRose said.

When the eye muscles are tired, some kids struggle to keep their eyes aligned and tracking to do things like read.

Their muscles just say I cant stay aligned all day, I cant stay focused all day, Im just going to give up and not do it, she said.

While a child or teen may avoid reading or doing schoolwork, they dont always avoid the screens that are making their eyes tired in the first place.

Dr. Glen Steele, an optometrist at the Southern College of Optometry in Memphis, Tenn., said kids will push through the pain to keep playing games or scrolling on social media. He thinks its leading to prolonged enlarged pupils, a phenomenon Steele calls defocus.

Steele's been tracking enlarged pupils for the last two years in his patients the worst case was in a 4-year-old. The kids will come into his office with dilated eyes that wont constrict for the entirety of the appointment, but hes not sure how long they stay dilated because he hasnt systematically tracked them outside the office.

Nonetheless, hes concerned about what hes been seeing.

Thats a persistent sympathetic response, he said. The sympathetic system controls heart rate, blood vessels, bronchial passageways, perspiration, blood pressure all those kinds of things. My concern now is, what is happening in the rest of the body if this is what Im seeing in the eye?

Steele said more research is needed to better understand what else is happening in the body and what the long term side effects may be.

Kids and teens arent the only ones who are impacted by too much screen time adults often fall into habits like checking Twitter first thing in the morning while still in bed which can cause smartphone-induced blindness.

When one eye is exposed to the light of a phone, and the other eye stays closed while the person in lying on their side, they may experience temporary blindness in the eye that was adapted to the phone screen light.

Start with the 20-20-20 rule. Take a break from staring at a screen every 20 minutes, and look at something 20 feet away for 20 seconds. DeRose said she recommends her patients program reminders in their phones.

For kids, Steele recommends more frequent breaks, and that parents set reminders and hold kids accountable. The World Health Organization released guidelines earlier this year that have recommendations for allotted screen time by age, but also on physical activity and sleep for children.

Steele recommends taking the WHO guidelines and going one step further, he offers parents and patients a few tips:

Visit link:
Staring At Screens All Day Hurts More Than Just Eyesight. Here's What To Do To Keep Your Vision Healthy - Colorado Public Radio

Read More...

Cannabis For Your Vision – Can It Improve Your Eyesight? – ProsperCBDNews

November 22nd, 2019 5:51 pm

Theres a lot of talk about what cannabis can and cannot do. The herb surely comes with many health benefits from alleviating chronic pain to reducing the severity and frequency of seizures. Now that weed has finally been added to the legal list in most states, it has become more accessible.

This brings us to what the substance can do for the eyes. There are mixed opinions in this regard some say cannabis can improve eye health while others disagree. Several research works show that CBD can be a treatment worth exploring for glaucoma. However, the American Academy of Ophthalmology doesnt favor the use of cannabis for glaucoma.

Ever noticed the red, almost bloodshot eyes of pot smokers? Thank cannabis for this effect. Cannabis lowers ocular pressure which causes capillaries to widen and pupils to dilate. While such reddened eyes look horrifying, the visual organs are actually relaxed. Other than this, cannabis also improves night vision. This gives some hope that the herb may help with eyesight as well.

This benefit of improved night vision is not due to CBD though. In fact, tetrahydrocannabinol, the psychoactive component of cannabis, takes the credit for that. One study found that the THC in cannabis interacts with the cannabinoid receptors in the eyes. By doing so, it can improve the ability to see at night.

Another indication that cannabis may improve vision is that it can reduce age-related blindness. Science shows that cannabis contains antioxidants that can reduce the risk of or slow down neurodegenerative blindness. Back in 2004, a group of fishmen claimed that they were able to see better when they consumed cannabis. Testing showed that they werent wrong.

Can you add cannabis to the list of foods that can improve your eyesight likes nuts, legumes, and carrots? Not much can be said about this. Research is scarce on the subject. In fact, if you look at the overall studies conducted on cannabis youll find that evidence on its effect in other areas of health is also limited.

One JAMA research concluded that cannabis can harm your sight overtime. Furthermore, some folks might also find that they are allergic to the herb. Since the long-term effects of what cannabis does to your eyes on the whole or your eyesight in particular are not known, its best to not use the herb. Some say that marijuana can only improve vision when you take it in high amounts. And intake of huge quantities of weed is not good for health.

Theres some research that shows that cannabis can be useful in some ways in the eye health department. It may help with glaucoma, but experts still dont agree on its use here. Weed can relax your eyes and also may improve night vision. However, since research is limited it is best to not use cannabis for vision or eye health.

Continued here:
Cannabis For Your Vision - Can It Improve Your Eyesight? - ProsperCBDNews

Read More...

A vision for the future – Pursuit

November 22nd, 2019 5:51 pm

A lot of people dont know a lot about eyes or how interesting they can be. They are the window to the body and there are so many illnesses that cause complications in the eyes. As a surgeon, when you specialise in eyes you get to work with a great variety of patients and to interact with lots of clinical groups and physicians.

When I started studying medicine, I hadnt decided on a speciality. I went to school in Geelong and became interested in medicine and general surgery when my mother had breast cancer. But it wasnt until my internship at the Royal Melbourne Hospital that I decided to specialise in eyes.

When I applied for a vitreoretinal surgery fellowship, all of the vitreoretinal surgeons in Australia were men. It was suggested that I should do medical retina rather than surgery. That was because surgery can be very busy and unpredictable and there is lots of after-hours and emergency work. It wasnt considered family friendly.

I had a great mentor. Gerard Crock, the first Professor of Ophthalmology at the University of Melbourne, was very encouraging of my career path and supported what I wanted to do. In 1995, I went to Moorfields Eye Hospital in London to do my final year of training. At the time, there was only one female vitreoretinal surgeon in the UK, and only one other woman training with me.

Read more

I like the precision of surgery. Vitreoretinal surgery involves operating on the very intricate structures of the vitreous humour and retina the lining of the back of the eye.

When you repair a retinal detachment, you are either preventing someone from going blind or restoring their sight. I also like treating patients who have had eye trauma. Its unpredictable, but you can get some wonderful outcomes.

I never imagined I would one day work with a bionic eye. Then in 2008, the Australia 2020 Summit happened, and the bionic eye was identified as a goal for the Australian community.

The timing was perfect. Teams from the Bionics Institute, Centre for Eye Research Australia, the University of New South Wales, the University of Melbourne and NICTA had just got together and Professor Hugh Taylor had approached another surgeon, Mark McCombe, and myself to help develop a surgical technique that enabled the safe insertion of the device.

The bionic eye takes images from a tiny camera on the persons glasses. It converts them into electrical signals that travel to an electrode array implanted in the wall between the eye and the retina.

The idea of the device is to provide what we call a sense of vision. Its not detailed vision its little flashes of light that can help people to detect edges, outlines and movement, which helps them to navigate the world and identify objects around them.

Its exciting to offer hope of restoring some sight and independence to people. These are people who have lost their sight because of inherited retinal diseases. For many years, people with these conditions were told there was nothing that could be done to help them.

Read more

All of our trial patients are altruistic and incredibly brave. In 2012, Dianne Ashworth was the first Australian patient to have a bionic eye implanted in our proof-of-concept trial. When she asked me if I had done the surgery on a person before, I had to say no, but she still decided to take the leap of faith and go ahead.

We are now progressing with another trial using a new second-generation device. We have four patients using the device at home and are really thrilled with the early results. After many years of having no sight, they are now able to do things like distinguish between dark and light items in washing or tell if someone is standing at a shop counter.

A project like the bionic eye is a huge collaboration. I still remember the first surgery in 2012. It couldnt have happened without the collaboration of the entire team at the Royal Victorian Eye and Ear Hospital, especially Robert Briggs and theatre staff who made a huge effort to lay out the theatre and get it ready for surgery.

Weve also relied heavily on the expertise of the Bionics Institute, who have worked really closely with our team at the Centre for Eye Research Australia to develop the first bionic eye and a second-generation device that we are now trialling.

There are now some really exciting developments in vision processing software. Right from the outset weve worked with Associate Professor Nick Barnes from the Australian National University (ANU). His research will continue to improve how the visual information is provided to patients.

Wed also like to investigate ways of using implanted devices to prevent vision loss, and also how these devices might be used together with gene and cell therapies to restore sight.

In the future we hope to be able to bring the bionic eye to more patients. We hope it will be something they can use to navigate the world independently in their daily lives.

- As told to Janine Sim-Jones

Associate Professor Penny Allen is presenting the Centre for Eye Research Australias 11th annual Gerard Crock Lecture on 21 November. The event will be live streamed from 6pm here.

Banner: Getty Images

Go here to read the rest:
A vision for the future - Pursuit

Read More...

Contact Lens That Helps Children with Nearsightedness FDA Approved – Healthline

November 22nd, 2019 5:51 pm

Share on PinterestChildren with nearsightedness often develop more serious eye problems later in life. Getty Images

Help is on the way for young children who have nearsightedness.

The Food and Drug Administration (FDA) has approved the first contact lens designed to slow the progression of myopia in children between 8 and 12 years old.

The MiSight contact lens is a soft, single use, disposable lens thats discarded at the end of each day without overnight use.

This is a big deal, because we hope this will finally put myopia control management in the spotlight, Dan Press, OD, FCOVD, an optometrist at Park Ridge Vision in Illinois, told Healthline.

There is a mountain of evidence supporting multiple options to slow the progression of childhood myopia, but the uptake has been slow since none of the treatments were FDA approved to specifically slow down myopia. Our hope is that this brings the discussion into the mainstream, and doctors that have not been on board in the past will get on board now, he said.

According to the FDA, myopia is the most frequent cause of correctable visual impairment across the world.

Myopia happens when the eye grows too long from front to back. Instead of focusing images on the retina, images are focused on a point in front of the retina.

People with myopia frequently have whats considered good vision, but they struggle with poor distance vision that usually must be addressed with glasses or contact lenses.

Myopia first occurs in primary and elementary-age children and progresses until about age 20, Dr. Rupa K. Wong, a pediatric ophthalmologist based in Honolulu, told Healthline.

In childhood, uncorrected myopia may impair childrens ability to fully participate in everyday activities, such as school, extracurriculars like sports, dance, and music, she said.

Myopia isnt just about improving a childs performance or limiting vision-related injuries on a field.

Theres a real question of health. And the sooner its dealt with, the better.

The prevalence and severity of myopia are increasing, especially in our current reading devicefocused culture, Wong said. Theres widespread acknowledgement that progression can be managed, but there needs to be more urgency to act earlier.

As if myopia alone isnt enough to deal with, research shows it can lead to other eye problems later in life.

Evidence has demonstrated that higher levels of myopia are associated with increased risk of retinal detachment, cataracts, glaucoma, and other vision-threatening issues later in life, Wong said.

She says not only can the new contact lens address the sight problems, it can also affect the elongation of the eye.

Individuals who are nearsighted typically have a longer eyeball than those who are not. Their higher axial length means that their retina gets stretched more compared to people who are not myopic. It could mean that these kids will be much less at risk for the development of retinal detachments, retinal tears, or even cataracts, as adults, Wong explained.

The approval of MiSight was based on data gathered from four clinical sites, according to the FDA.

Its safety and effectiveness were studied in a 3-year, randomized controlled clinical trial of 135 children, ages 8 to 12 years, who used MiSight or a conventional soft contact lens.

The trial showed that for the first 3-year period, progression of myopia in those using MiSight was less than those wearing conventional lenses.

MiSight participants also had less change in the axial length of the eyeball at each annual checkup. There were no serious ocular adverse events reported during the study.

Though those trials were done for use in the United States, theres also plenty of anecdotal evidence from around the world, where MiSight has already been in use for a significant amount of time.

This is terrific news for our eye care practitioner colleagues in the United States, Damon Ezekiel, B Optom, FAAO, FCLSA, an Australian optometrist and the president of the International Society of Contact Lens Specialists, told Healthline.

We are very fortunate that we in Australia have had access to the MiSight lens, along with Canada, United Kingdom, and Spain. This brings the United States in line with so many countries.

Personally, I have quite a number wearing MiSight. All of our patients who have been wearing the MiSight lenses are very happy. Their visual acuities are stable, and they love the convenience of wearing a daily disposable lens, Ezekiel said.

Link:
Contact Lens That Helps Children with Nearsightedness FDA Approved - Healthline

Read More...

Page 800«..1020..799800801802..810820..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick